Abstract LB277: Exposure response and safety analysis of osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC patients with EGFRm (FLAURA2)

培美曲塞 奥西默替尼 医学 肿瘤科 化疗 内科学 第一行 顺铂 癌症 腺癌 ROS1型
作者
Jincheng Yang,Damilola Olabode,Aarti Sawant,Karthick Vishwanathan,Srinivas Bachina,A. Todd,Dana Ghiorghiu,Yuri Rukazenkov,Alex Phipps,Diansong Zhou,Azar Shahraz
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (7_Supplement): LB277-LB277
标识
DOI:10.1158/1538-7445.am2024-lb277
摘要

Abstract Osimertinib (Osi) is a potent, CNS-active irreversible inhibitor of epidermal growth factor receptor-mutate (EGFRm) and T790M mutations. It is currently approved as the standard of care in patients with locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR-TKI therapy and as the first-line agent in patients with locally advanced or metastatic EGFRm NSCLC. FLAURA2 is a global, randomized, open-label, multi-center phase III clinical study to investigate the safety and efficacy of Osi 80 mg once daily in combination with platinum-pemetrexed chemotherapy compared to Osi monotherapy, as a first-line treatment in patients with locally advanced or metastatic EGFRm NSCLC. This study is ongoing and an sNDA has been submitted for approval. The objectives of this current analyses were to 1) assess the exposure-efficacy relationship between population PK model-derived Osi exposure metrics (AUCss, Cmaxss, Cminss), and PFS in patients from the investigational arm (Osi + chemotherapy arm, n=244) of FLAURA2 study and 2) assess the relationship between Osi exposure metrics and key safety endpoints. The exposure response (ER) relationship between Osi and progression free survival (PFS) in patients enrolled in the investigational arm of FLAURA2 was assessed. Kaplan Meier plots with patients stratified by quartile exposure of Osi in the investigational arm indicated no clear ER relationship, though there appears to be a trend of lower PFS with highest AUCss quartile. A stepwise Cox proportional hazard analysis indicated that the effect of Osi exposure metrics were not statistically significant associated with PFS; however, the number of pemetrexed cycles appeared to be a significant covariate on PFS. The relationship between Osi exposure metrics and AEs CTCAE Grade 3 and above causally related to Osi, as well as AESIs from the investigational arm of FLAURA2 study were explored. The graphical exploration and logistic regression analysis did not identify statistically significant relationship of Osi exposures on CTCAE ≥ Grade 3 adverse events (AEs) causally related to Osi, AEs leading to Osi dose interruptions/reductions/discontinuations, and AESIs including ≥ Grade 3 haematological AEs, cardiac effects, left ventricular ejection fraction decrease and ≥ Grade 1 interstitial lung disease causally related to Osi. In conclusions, no statistically significant relationships between exposure of Osi and response were observed, supporting the recommended dose of Osi of 80 mg daily in the FLAURA2 patient population. Overall, the recommended dose of Osi as monotherapy or in combination with chemotherapy is 80 mg once daily, with a dose reduction to 40 mg daily if unacceptable toxicity is observed. Citation Format: Jincheng Yang, Damilola Olabode, Aarti Sawant, Karthick Vishwanathan, Srinivas Bachina, Alexandar Todd, Dana Ghiorghiu, Yuri Rukazenkov, Alex Phipps, Diansong Zhou, Azar Shahraz. Exposure response and safety analysis of osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC patients with EGFRm (FLAURA2) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB277.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HotnessK完成签到,获得积分10
1秒前
皮皮发布了新的文献求助10
1秒前
棒棒糖发布了新的文献求助30
2秒前
3秒前
传奇3应助moyue采纳,获得10
3秒前
3秒前
zjx发布了新的文献求助10
4秒前
Tiinsiin完成签到,获得积分10
4秒前
4秒前
5秒前
果仁鼠大王完成签到,获得积分10
5秒前
Sandy完成签到,获得积分10
5秒前
顾矜应助WC采纳,获得10
5秒前
qiaokizhang发布了新的文献求助10
6秒前
7秒前
迦佭完成签到,获得积分10
7秒前
am发布了新的文献求助10
7秒前
8秒前
量子星尘发布了新的文献求助10
8秒前
健忘傲柏完成签到,获得积分10
8秒前
wjx发布了新的文献求助10
8秒前
8秒前
你说的完成签到 ,获得积分10
9秒前
乌拉挂机完成签到,获得积分10
9秒前
9秒前
蘑菇丰收完成签到,获得积分20
9秒前
bela完成签到,获得积分10
9秒前
小蘑菇应助科研通管家采纳,获得20
10秒前
Bryan应助科研通管家采纳,获得10
11秒前
乌拉挂机发布了新的文献求助10
11秒前
yar应助科研通管家采纳,获得10
11秒前
完美世界应助科研通管家采纳,获得20
11秒前
科研通AI5应助科研通管家采纳,获得10
11秒前
yar应助科研通管家采纳,获得10
11秒前
11秒前
大个应助科研通管家采纳,获得10
11秒前
11秒前
11秒前
11秒前
mc应助科研通管家采纳,获得10
11秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974943
求助须知:如何正确求助?哪些是违规求助? 3519467
关于积分的说明 11198482
捐赠科研通 3255728
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877261
科研通“疑难数据库(出版商)”最低求助积分说明 806224